Kevin Dennis Hill, MD

Associate Professor of Pediatrics
Associate of the Duke Initiative for Science & Society
Member in the Duke Clinical Research Institute
Campus mail:
DUMC Box 3090, Durham, NC 27710
Phone:
(919) 668-8305
Email address:
kevin.hill@duke.edu
Clinical research including outcomes, drug and device trials, short and long term safety and efficacy of interventions and hemodynamic effects of interventions.
Education and Training
- Interventional Fellowship, Pediatrics, Vanderbilt University, 2008 - 2009
- Pediatric Cardiology Fellowship, Pediatrics, Vanderbilt University, 2005 - 2008
- Pediatric Residency, Pediatrics, Wake Forest University, 2002 - 2005
- M.D., Wake Forest University, 2002
Selected Grants and Awards
- The North Carolina Congenital Heart Disease Surveillance Network
- TOMORROW: pediaTric use Of Macitentan tO delay disease pRogRessiOn in PAH Worldwide
A multicenter, open-label, randomized, event-driven study to assess efficacy, safety and pharmacokinetics of macitentan - Fontan Udenafil Exercise Longitudinal Assessment Trial
- A Prospective, Open -Label Active -Controlled study to Evaluate the Pharmacokinetics Pharmacodynamics, Saftey and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan procedure
- Bridging the Gap to Enhance Clinical Research Program (BIGGER)
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- Evaluating post-op AKI criteria in infants with CHD and the protective effects of acetaminophen
- Leveraging registry resources for efficient and cost effective clinical trials
- Steriods to Reduce Systemic inflammation after neonatal hart Surgery
- Understanding Quality and Costs in Congenital Heart Surgery
- North Carolina Congenital Heart Defects Surveillance Network
- Fontan Udenafil Exercise Longitudinal Assessment Trial-OLE
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- The Congenital Heart Technical Skill Study: Improving Outcomes for Infants and Children with Congenital Heart Disease
- Duke CTSA (KL2)
- Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Children with Single Ventricle Heart Defects.
- Evaluation of endothelial function in single ventricle patients receiving Ambrisentan after surgery.
- Institutional Training Grant in Pediatric Cardiology
- PHN Scholar's grant